Navigation Links
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Date:11/6/2008

8 (p < 0.0001) and 20.7 at Week 16 (p = 0.02). Immune monitoring performed in three of four patients who underwent repeat treatment suggested an increase in immune response following the booster treatments. Five patients had prolonged disease stabilization ranging from 48 to 94 weeks, without the addition of other cancer therapy other than the continuation of bisphosphonates. In addition, one patient experienced a partial response lasting approximately six months.

"We were pleased to see consistent results across both NEUVENGE trials, particularly as they further substantiate the tolerability of this therapeutic approach," stated Mark Frohlich, M.D., senior vice president, clinical affairs and chief medical officer. "These data provide further evidence of the promise of our active cellular immunotherapy platform which also includes PROVENGE(R) (sipuleucel-T), our lead product candidate currently in late-stage development for prostate cancer. We expect to receive the final data analysis from our ongoing Phase 3 PROVENGE trial in mid-2009 and look forward to discussing further clinical development plans for NEUVENGE and our immunotherapy pipeline after that time."

About NEUVENGE

NEUVENGE (lapuleucel-T) is an investigational product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. ACIs hold promise because they may provide patients with a meaningful clinical benefit with low toxicities. NEUVENGE is designed to stimulate cellular immune responses against HER2/neu. HER2/neu is over-expressed in a variety of solid tumors, including breast, colorectal, bladder and ovarian cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commerc
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 2, 2015 Nevro Corp. (NYSE: ... providing innovative evidence-based solutions for the treatment of chronic ... public offering of its common stock at a public ... The offering consists of 1,764,705 shares to be sold ... certain of its stockholders, resulting in aggregate proceeds of ...
(Date:6/2/2015)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), a biopharmaceutical ... for the treatment of central nervous system disorders, today ... President and CEO, will deliver a corporate presentation at ... York City on Thursday, June 4, 2015 ... at the Jefferies Global Healthcare Conference will be available ...
(Date:6/2/2015)... , June 2, 2015  Endo International plc (NASDAQ: ... announced today that it has commenced an underwritten public ... All ordinary shares in the offering are to be ... also grant to the underwriters of the Offering an ... the date of the final prospectus supplement, to purchase ...
Breaking Medicine Technology:Nevro Announces Pricing of Upsized Public Offering of Common Stock 2Nevro Announces Pricing of Upsized Public Offering of Common Stock 3Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 2Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 3Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 4
... 23, 2011 A recently enacted standard has replaced ...  This superseding standard, the Statement on Standards for Attestation ... 15, 2011 and pushes service organizations to enforce a ... (Logo: http://photos.prnewswire.com/prnh/20080206/AQW030LOGO-b ) Rising ...
... 23, 2011 Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... presenting at the Jefferies 2011 Global Healthcare Conference in ... Officer of Unilife, is scheduled to present at 5:00 ... Wednesday, September 28, 2011. The conference presentation ...
Cached Medicine Technology:Rising Medical Solutions, an Early Adopter of SAS 70's Replacement Standard 2Rising Medical Solutions, an Early Adopter of SAS 70's Replacement Standard 3Unilife to Present at the Jefferies 2011 Global Healthcare Conference in London 2
(Date:6/2/2015)... Concorde Career Colleges, Inc., announced today the appointment ... manage day-to-day operations for the privately held career college ... to help our Concorde team deliver on our commitment ... part due to reports like Beyond College Rankings from ... and Portland.” , Bell brings 14 years of executive ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 MEDIA ... Wallace, 571-319-9594 (cell) , Email: ewallace(at)mentalhealthamerica(dot)net , Breaking ... New Mental Health Legislation at MHA Annual Conference ... What: Rep. Murphy to address the Mental Health ... the long-awaited updated version of the Helping Families ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 On Wednesday, May ... Supercharged Mustang to a top speed of 207.9 mph. ... 2015 Mustang to break the 200 mph mark. Jay ... filming an upcoming episode of Jay Leno’s Garage, which will ... made on the 8.5 mile high speed oval at the ...
(Date:6/2/2015)... 2015 The Down Syndrome Association of ... the hit show Glee as the keynote speaker for ... Pleasant Prairie, WI. The event aims to raise funds ... Kenosha, and Walworth counties. , "We ... for this important event," says Dawn Nuoffer, DSAW Executive ...
(Date:6/2/2015)... 02, 2015 The term “Augmented Reality” ... imagery overlaid on the real world. Since then many ... which displays a map of the vasculature on the ... in adoption. , AccuVein, the leader in vein visualization, ... growth rate and such widespread adoption of its AccuVein ...
Breaking Medicine News(10 mins):Health News:Concorde Career Colleges Announces New President and COO 2Health News:Congressman Tim Murphy to Unveil Details of New Mental Health Legislation at MHA Annual Conference Thursday 2Health News:774 HP Hennessey Mustang Tested to 207.9 mph 2Health News:Glee star Lauren Potter helps Down Syndrome Association of WI raise awareness, support 2Health News:Vein Visualization Emerges as Premier Augmented Reality Application 2
... Package Provided in NDA Demonstrates ... Tramadol Formulation, LAVAL, QC, Sept. 24 /PRNewswire-FirstCall/ - ... has requested a meeting with the U.S.,Food and Drug ... its once-daily formulation of tramadol. Based on,additional analysis that ...
... Sept. 24 Sister Carol Keehan,DC, president and ... the United States (CHA), issued the following statement. ... compromise to,reauthorize the State Children,s Health Insurance Program ... the legislation. Reauthorizing SCHIP represents the most ...
... need to look beyond the renal arteries when doing renal ... in Rochester, MN suggests. The study found that 98% ... additional vascular or nonvascular findings. , The study included 380 ... 151 (40%) of these patients had one or more additional ...
... future,missions to the moon and Mars could face serious ... National Space Biomedical Research,Institute, known as NSBRI, Houston, will ... better understand and reduce those risks. Scientists at,universities, research ... studies. The goal of NASA,s space radiation research ...
... finds real improvements compared to standard therapy , MONDAY, ... Chinese or even sham acupuncture treatment appeared more effective ... German study of almost 1,200 patients. , Traditional ... points on the body to a depth of 5 ...
... Offer Retirement Solution to Large Corporations, NEW ... announced today that it has hired Bill McDermott ... also been named a member of the,company,s Executive ... retirement solutions for Fortune 1000 companies. The,announcement was ...
Cached Medicine News:Health News:Labopharm provides update on U.S. regulatory process for once-daily Tramadol 2Health News:Labopharm provides update on U.S. regulatory process for once-daily Tramadol 3Health News:Catholic Health Association to Congress and President Bush: Uninsured Children Need Your Help Now 2Health News:NASA, NSBRI Select 17 Proposals in Space Radiation Research 2Health News:Even Sham Acupuncture Eases Low Back Pain 2Health News:AXA Equitable Life Insurance Co. Hires William McDermott to Lead Corporate Retirement Planning Business 2Health News:AXA Equitable Life Insurance Co. Hires William McDermott to Lead Corporate Retirement Planning Business 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: